A 2022 clinical trial investigated ELK1 among other potential biomarkers as a distinctive molecular signature of either urothelial bladder cancer (UBC) or upper tract urothelial carcinoma (UTUC) [255]. This evidence concerns the gene ELK1 and renal pelvis/ureter urothelial carcinoma.